A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol
NCT00644670
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Dyslipidemia
- At a high risk for coronary heart disease
- Use of higher than usual maintenance doses of statin drugs at screening
- Uncontrolled diabetes or high blood pressure
- Impaired liver function
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Daegu, Korea
- Seoul, Korea
- Busan,
- Busan,
- Daegu,
- Daejeon,
- Gwangju,
- Gwangju,
- Gyeonggi-do,
- Gyeonggi-do,
- Incheon,
- Kyunggi-do,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Antwerpen,
- Brasschaat,
- Brussels,
- Edegem,
- Genk,
- Gent,
- Gilly (charleroi),
- La Louvière,
- Liège,
- Mechelen,
- Menen,
- Merksem,
- Mortsel,
- Roeselare,
- Seraing,
- Wilrijk,
- Wingene,
- Antwerpen,
- Brasschaat,
- Brussels,
- Genk,
- Gent,
- Gilly (charleroi),
- La Louvière,
- Mechelen,
- Menen,
- Merksem,
- Mortsel,
- Roeselare,
- Seraing,
- Wilrijk,
- Wingene,
- Belo Horizonte, MG
- Curitiba, PR
- Porto Alegre, RS
- Porto Alegre, RS
- São José, SC
- São Paulo, SP/Brazil
- Campinas, SP
- Campinas, SP
- Sao Paulo, SP
- Sao Paulo, SP
- São José do Rio Preto, SP
- São Paulo, SP
- Rio de Janeiro,
- Santiago, Región Metropolitana
- Bogota, Cundinamarca
- Bogotá, Cundinamarca
- Barranquilla,
- Bogotá, C/marca,
- Cali, Valle,
- Quito, Pichincha / Ecuador
- Guatemala,
- Guadalajara, Jalisco
- Zapopan, Jalisco
- Monterrey, Nuevo Leon
- Monterrey, Nuevo Leon
- Chihuahua,
- Durango,
- Panama,
- Dtto. Federal, Caracas
- Caracas, Dtto Federal
- Caracas, Dtto Federal
- Caracas, Edo. Miranda
- Caracas,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol | |||
Official Title ICMJE | A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving LDL Cholesterol Targets With Atorvastatin Starting Doses Of 10 Mg, 20 Mg And 40 Mg. | |||
Brief Summary | The purpose of the study is to evaluate the effectiveness of atorvastatin in lowering cholesterol and getting these high risk patients to their goals of LDL <115 mg/dl across starting doses of 10 mg, 20 mg, or 40 mg with one step titration. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Dyslipidemias | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 232 | |||
Original Actual Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | March 2004 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 30 Years to 80 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Belgium | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00644670 | |||
Other Study ID Numbers ICMJE | A2581099 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | March 2008 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |